We make novel antibody medicines to treat cancers and rare diseases.
- Project: [page_title] & BTI. Proof of concept of the efficacy. Design of experiments using ONENA additive combined with PRGF in term of cell proliferation.
Articles related with [page_title]
2929/01/2019
Gerard Vidal (Enigmedia): “Bind 4.0 has allowed us to focus on the industrial market”
Gerard Vidal at BIND Gerard Vidal is one of the founders and CEO of Enigmedia, a security startup that offers products to protect connected networks. Thanks to Bind 4.0, it has shifted its focus to the industrial market, where it sees a larger market to grow either by offering direct [...]
2424/01/2019
Jon Matias and Jokin Garay (Keynetic): “Thanks to Bind 4.0 we have been able to introduce our technology to real customers”
Jon Matias and Jokin Garay at BIND Jon Matias and Jokin Garay founded Keynetic Technologies one year ago as a university spinoff. Their research had allowed them to develop a cybersecurity product for industrial plants but they needed to test it with real customers. First they founded the company and, [...]
